• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Augmenix debuts SpaceOar in Israel

June 30, 2017 By Sarah Faulkner

AugmenixAugmenix Inc. said this week that it launched its SpaceOar hydrogel device in Israel.

The Bedford, Mass.-based company’s absorbable prostate-rectum spacer is designed to reduce rectal injury during prostate radiotherapy.

“We are excited to offer our patients this new, innovative technology to significantly reduce risks of prostate cancer radiotherapy,” Dr. Zvi Symon, from the Chaim Sheba Medical Center, said in prepared remarks. “SpaceOar hydrogel will provide meaningful long-term benefits, improving overall quality of life for our patients.”

“We are extremely pleased to bring our innovative SpaceOar hydrogel to physicians and patients in Israel,” CEO John Pedersen added. “Our growing body of clinical evidence demonstrates that SpaceOar hydrogel significantly reduces the risk of rectal and urinary toxicities and loss of sexual function associated with prostate cancer radiotherapy. SpaceOar hydrogel is making a significant difference in the lives of men around the world.”

In January, the company touted data showing that patients treated with SpaceOar prior to prostate cancer radiotherapy had significant rectal, urinary and sexual benefit 3-years following treatment.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Oncology, Wall Street Beat Tagged With: Augmenix

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS